Saxenda Effectively Reduces BMI in Children Aged 6 to 12, According to NEJM Study
Saxenda's Significant Impact on Childhood Obesity
A study published in The New England Journal of Medicine reveals that Saxenda, containing liraglutide, effectively lowers BMI in children aged six to twelve years. Over a span of 56 weeks, patients using Saxenda experienced an average BMI reduction of 5.8%, in contrast to a 1.6% increase in the placebo group.
Study Details and Findings
- The Phase IIIa study included 82 participants.
- Children in the Saxenda group had a weight increase of only 1.6%
- Statistical significance found with p-value < 0.001.
Despite some gastrointestinal side effects noted, both treatment groups reported common adverse events. Lead researcher Claudia Fox highlighted the urgency of addressing childhood obesity, as untreated conditions can lead to diabetes and cardiovascular diseases later in life.
The Importance of Early Intervention
With obesity projected to cause significant health issues, early intervention through medications like Saxenda could be vital. As childhood obesity remains a critical issue, understanding treatment options becomes crucial for parents and healthcare professionals.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.